NASDAQ:INHX - Inhibitex Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Inhibitex, Inc. develops antibody-based products for the treatment and prevention of bacterial and fungal infections. The Company produces products that can be used as vaccines, binding inhibitors or separation supports for affinity purifications. The Company's lead product candidate, Veronate, which entered into Phase III clinical trial in the second half of 2004, is being developed for the prevention of hospital-associated infections in premature, very low birth weight, (VLBW) infants.

Receive INHX News and Ratings via Email

Sign-up to receive the latest news and ratings for INHX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:INHX
Previous Symbol
CUSIPN/A
Phone+1-678-7461100

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable

Inhibitex (NASDAQ:INHX) Frequently Asked Questions

What is Inhibitex's stock symbol?

Inhibitex trades on the NASDAQ under the ticker symbol "INHX."

Has Inhibitex been receiving favorable news coverage?

Media coverage about INHX stock has been trending somewhat positive recently, InfoTrie reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Inhibitex earned a coverage optimism score of 2.0 on InfoTrie's scale. They also gave media headlines about the healthcare company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days.

How do I buy shares of Inhibitex?

Shares of INHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Inhibitex's official website?

The official website for Inhibitex is http://www.inhibitex.com.

How can I contact Inhibitex?

Inhibitex's mailing address is 9005 Westside Pkwy, ALPHARETTA, GA 30009-4783, United States. The healthcare company can be reached via phone at +1-678-7461100.


MarketBeat Community Rating for Inhibitex (NASDAQ INHX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  113 (Vote Outperform)
Underperform Votes:  81 (Vote Underperform)
Total Votes:  194
MarketBeat's community ratings are surveys of what our community members think about Inhibitex and other stocks. Vote "Outperform" if you believe INHX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INHX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2018 by MarketBeat.com Staff

Featured Article: What is the LIBOR?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel